Titre :

Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections.

Auteur(s) :

Moreau, Anne-Sophie [Auteur]
Martin-Loeches, Ignacio [Auteur]
Povoa, Pedro [Auteur]
Salluh, Jorge [Auteur]
Rodriguez, Alejandro [Auteur]
Thille Arnaud, W [Auteur]
Diaz Santos, Emilio [Auteur]
Vedes, Elisa [Auteur]
Margareth Lobo, Suzana [Auteur]
Megarbane, Bruno [Auteur]
Molero Silvero, Esperanza [Auteur]
Coelho, Luis [Auteur]
Arnaud, Laurent [Auteur]
Sanchez Iniesta, Rafael [Auteur]
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Rouze, Anahita [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Nseir, Saad [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995

Titre de la revue :

The European respiratory journal

Nom court de la revue :

Eur. Respir. J.

Date de publication :

2018-02-08

ISSN :

1399-3003

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The aim of this planned analysis of the prospective multinational TAVeM database was to determine the incidence, aetiology and impact on outcome of ventilator-associated lower respiratory tract infections (VA-LRTI) in ...
Lire la suite >The aim of this planned analysis of the prospective multinational TAVeM database was to determine the incidence, aetiology and impact on outcome of ventilator-associated lower respiratory tract infections (VA-LRTI) in immunocompromised patients.All patients receiving mechanical ventilation for >48 h were included. Immunocompromised patients (n=663) were compared with non-immunocompromised patients (n=2297).The incidence of VA-LRTI was significantly lower among immunocompromised than among non-immunocompromised patients (16.6% versus 24.2%; sub-hazard ratio 0.65, 95% CI 0.53-0.80; p<0.0001). Similar results were found regarding ventilator-associated tracheobronchitis (7.3% versus 11.6%; sub-hazard ratio 0.61, 95% CI 0.45-0.84; p=0.002) and ventilator-associated pneumonia (9.3% versus 12.7%; sub-hazard ratio 0.72, 95% CI 0.54-0.95; p=0.019). Among patients with VA-LRTI, the rates of multidrug-resistant bacteria (72% versus 59%; p=0.011) and intensive care unit mortality were significantly higher among immunocompromised than among non-immunocompromised patients (54% versus 30%; OR 2.68, 95% CI 1.78-4.02; p<0.0001). In patients with ventilator-associated pneumonia, mortality rates were higher among immunocompromised than among non-immunocompromised patients (64% versus 34%; p<0.001).Incidence of VA-LRTI was significantly lower among immunocompromised patients, but it was associated with a significantly higher mortality rate. Multidrug-resistant pathogens were more frequently found in immunocompromised patients with VA-LRTI.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Fungal associated invasive and inflammatory diseases
Glycation from inflammation to aging

Date de dépôt :

2019-03-01T14:17:57Z